Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413276 | 0.80 | CHRNB2 (0.32) | MEN1KMT2AP2RX7HSD11B1CYP17A1 | |
| SCHEMBL1769985 | 0.79 | P2RX7 (0.42) | MEN1KMT2AP2RX7HSD11B1CNR2 | |
| SCHEMBL1770241 | 0.77 | HSD11B1 (0.62) | MEN1KMT2AHSD11B1CYP17A1CYP19A1 | |
| SCHEMBL13688887 | 0.76 | HSD11B1 (0.56) | MEN1KMT2AHSD11B1CYP17A1CYP19A1 | |
| SCHEMBL30421834 | 0.65 | POLB (0.51) | MEN1KMT2ATSPOOPRK1 | |
| SCHEMBL4732085 | 0.64 | TGM2 (0.42) | MEN1KMT2AP2RX7CYP17A1CYP19A1 | |
| SCHEMBL19049440 | 0.62 | MTNR1A (0.64) | MEN1KMT2A | |
| SCHEMBL91395 | 0.62 | CA12 (0.50) | MEN1KMT2ATSPOOPRK1 | |
| SCHEMBL31444905 | 0.62 | HSD17B10 (0.54) | MEN1KMT2ATSPOOPRK1 | |
| SCHEMBL4732088 | 0.61 | MEN1 (0.45) | MEN1KMT2ACYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2257528-A2 | 1 IBETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106817-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | MEN1 2644/4885KMT2A 2328/4885P2RX7 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.